This is Michael Brady Lynch, lead trial attorney for the The Michael Brady Lynch Firm.

On top of the overuse and misuse of the Z Pak, there now there is some troubling data about an association of the Z Pak with cardiac complications. This week, the FDA notified healthcare professionals that it is aware of the study published in the New England Journal of Medicine  May 17, 2012 reporting a small increase in cardiovascular deaths, specifically prolongation of the QT interval, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug.
My readers can access the MedWatch safety alert, including a link to the Drug Safety Communication at:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm304503.htm
To be fair to the Z Pak, drug induced prolongation of the QT interval is nothing new and numerous drugs carry such warnings. But, QT wave prolongation is nothing to take lightly. With a QT abnormally prolonged or shortened, there is a risk of developing ventricular arrhythmia.
As a consumer advocate, what worries me the most about this data is the lack of meaningful communication to the public about the association between the Z Pak and prolongation of the QT interval. I would be happy to offer anyone who has suffered cardiac complications after taking a Z Pak a free, no-oligation consultation.
About the Firm: The Michael Brady Lynch Firm is a trial firm with a focus on pharmaceutical mass tort cases involving SSRI and Anti-Seizure Medication Birth Defects such as Lexapro, Zoloft, Effexor, Prozac, Celexa, Paxil, Depakote and Topamax, as well as Actos Bladder Cancer and Fosamax Femur Fractures, and medical device cases including DePuy Hip and Trans-Vaginal Mesh cases. Contact us today if you or someone you know has experienced side effects involving these products.